Calyx Consulting

“An investment in knowledge pays the best interest.”
- Benjamin Franklin

Put Calyx’s experience to work for you.

Calyx is an industry leader in delivering the solutions pharmaceutical companies and Clinical Research Organizations (CROs) need to:

  • Improve the reliability of data when imaging biomarkers are used in clinical trials
  • Optimize randomization and trial supply management so trials run effectively
  • Ensure worldwide regulatory requirements are met, every time

Having supported over 650 new drug approvals, Calyx scientific, technical, and regulatory experts possess a depth and diversity of experience that’s unmatched and are prepared for whatever the drug development and regulatory compliance process throws at them.  Contact us now to learn how Calyx consultants can help you meet your development objectives and pave your way to success.

Meet the experts.

Extend the deep and diverse experience of Calyx’s highly tenured scientific, technical, and regulatory experts to your own clinical development team.

Minimize risks in clinical trial imaging, RTSM, and regulatory information management. Contact us today.


Calyx CTMS: Powerful Functionalities

Containing all operational trial data, the CTMS solution allows consistent and accurate information to be shared across the entire enterprise, thereby facilitating timely and informed decision-making.
Read more

The Future of Calyx CTMS is on Azure

Now we’re taking the next step for Calyx CTMS, delivering Cloud-based technology to optimize CTMS efficiencies. All our innovation is taking place on Microsoft Azure cloud.
Read more

Assessing Prostate Cancer on Imaging in Clinical Trials

This whitepaper highlights Calyx’s expertise in using and adapting the PCWG3 criteria to address imaging-based objectives and endpoints in prostate cancer clinical trials.
Read more

Increase Efficiencies through Effective IRT Partnering

How can a program management approach combined with IRT standards overcome obstacles, alleviate RTSM-related pressures, and allow study teams to focus on other clinical development needs? Read the Case Study.
Read more